GLP-1–Based Therapies Significantly Reduce Inflammation in Cardiometabolic Disease: Meta-Analysis
China: Research presented at the International Congress on Obesity showed that incretin-based therapies (GLP-1 receptor agonists) significantly lower high-sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation, in adults with cardiometabolic conditions. Compared with placebo, adults with obesity experienced a 48% greater reduction in CRP, while patients with heart failure with preserved ejection fraction (HFpEF) had a 38% greater decrease, highlighting the anti-inflammatory benefits of GLP-1–based treatments beyond their metabolic effects.
Supporting this growing body of evidence, a systematic review and meta-analysis published in the Journal of Diabetes and Its Complications found that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduced serum C-reactive protein (CRP) levels in patients with type 2 diabetes mellitus. The study, led by Mohsen Mazidi of the Key State Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, evaluated randomized controlled trials to determine the effect of GLP-1 RAs on systemic inflammation.
CRP is a widely used marker of inflammation and has been linked to an increased risk of cardiovascular disease and diabetes-related complications. While GLP-1 receptor agonists are primarily prescribed to improve blood glucose control and promote weight loss, emerging evidence suggests these drugs may also exert anti-inflammatory effects. The researchers therefore conducted a comprehensive review to better quantify this potential benefit.
For the analysis, investigators searched PubMed-Medline, SCOPUS, Web of Science, and Google Scholar for randomized prospective studies published up to March 16, 2016. Eligible trials assessed changes in serum CRP levels following treatment with GLP-1 receptor agonists. The pooled data were analyzed using a random-effects model, while sensitivity analyses, heterogeneity testing, and meta-regression were performed to assess the robustness of the findings and identify factors influencing treatment effects.
Key Findings:
- The meta-analysis of seven treatment arms showed that GLP-1 receptor agonist therapy significantly reduced serum CRP concentrations, with a pooled weighted mean difference of −2.14 mg/dL.
- Sensitivity analysis confirmed the robustness of the findings, as removing individual studies did not significantly change the overall reduction in CRP levels.
- Longer treatment duration was associated with greater reductions in serum CRP, suggesting that sustained GLP-1 receptor agonist therapy may provide stronger anti-inflammatory benefits.
The authors concluded that GLP-1 receptor agonists significantly reduce serum CRP concentrations in patients with type 2 diabetes mellitus, reinforcing evidence that these medications offer benefits beyond glycemic control. The observed reduction in inflammatory markers suggests that GLP-1–based therapies may contribute to lowering the inflammatory burden associated with type 2 diabetes and its cardiovascular complications, although further large-scale studies are needed to better define their long-term clinical impact.
Reference:
Mazidi M, Karimi E, Rezaie P, Ferns GA. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications. 2017 Jul;31(7):1237-1242. doi: 10.1016/j.jdiacomp.2016.05.022. Epub 2016 May 30. PMID: 28479155.
Next Story